Chronic pulmonary disease with *Mycobacterium abscessus* complex is a biofilm infection

To the Editor:

Direct evidence of *Mycobacterium abscessus* complex (MABSC) biofilm in the human lung has not previously been demonstrated. Biofilms are microcolonies of bacteria, imbedded in extracellular matrix, providing stability and tolerance to antibiotics and the body’s innate and adaptive defences [1]. This mode of growth is an inherent feature of chronic infections and is particularly well studied for *Pseudomonas aeruginosa* and other Gram-negative infections [1], but also some *Staphylococcus aureus* infections [2]. Mycobacterial infections have also been shown to be capable of biofilm formation, most notably *Mycobacterium tuberculosis* (tuberculosis), which under the right conditions, can self-assemble into highly organised matrix-encapsulated biofilm [3]. Among the nontuberculous mycobacteria (NTM), *Mycobacterium avium* complex (MAC) and the rapidly growing mycobacteria, including MABSC, have been shown to grow as biofilms either in vitro or in environmental reservoirs [4, 5], but in vivo conditions have not been studied. MABSC is an emerging threat to patients with cystic fibrosis [6], who become infected at an early age and deteriorate clinically [7] as the persistent infection causes inflammation and tissue damage. We wanted to explore how MABSC grows in the antibiotic-rich, end-stage lungs of patients with cystic fibrosis. The aim was to describe the localisation and growth patterns of MABSC in vivo from freshly explanted lungs of patients with cystic fibrosis and a history of MABSC. We simultaneously performed histological and mycobacterial sampling from the same areas, from multiple pulmonary sites. Mycobacterial culture was performed by inoculation on at least one solid (Middlebrooke 7H10 or Löwenstein-Jensen slopes; SSI Diagnostica, Hilleroed, Denmark) and in one liquid culture medium (BACTEC 12B or MGIT; Becton Dickinson Microbiology Systems, Sparks, MD, USA), and a reverse hybridisation DNA assay was performed (InnoLiPA; Fujirebio Europe, Brondby, Denmark), as previously described [7]. Culture morphology was determined by direct visual inspection of colonies and control microscopy used Ziehl–Neelsen staining. Concomitant culture for Gram-negative and -positive bacteria was also performed. Patient files were reviewed to determine the clinical course of their end-stage lung disease and their history of other chronic bacterial infections. The NTM collection and clinical data collection was approved by the Committee on Health Research Ethics in the Capital Region of Denmark (Copenhagen, Denmark) (H-3-2012-098). The explanted lungs were collected by the transplantation team, microbiological samples were sent for NTM culture and histological samples were transferred to 4% formaldehyde before further preparation for microscopic investigation. The biopsy material was embedded in paraffin, cut into 4-μm sections and mounted on glass slides. Prior to microscopy, paraffin was removed and the tissue sections were analysed by means of conventional haematoxylin and eosin (H&E) staining, Ziehl–Neelsen staining (acid-fast stain), auramine dye (fluorescent stain), and fluorescent in situ hybridisation (FISH) with peptide nucleic acid (PNA) probes: a uniBac probe (red) and a NTM-specific probe (green) (AdvanDx, Inc., Woburn, MA, USA). We used 4′,6′-diamidino-2-phenylindole (Vector Laboratories) as a counterstain for DNA. Microscopic observations were performed with Zeiss 710 Confocal Laser Scanning Microscope (Leica Microsystems, Mannheim, Germany).

Six patients with either active (n=5) or prior (n=1) MABSC infection were included. None had a history of infection with other NTM species. The five patients with active MABSC disease were in intravenous or oral multidrug antimycobacterial treatment at the time of transplantation. Their clinical outcomes have previously been published [8]. MABSC was cultured from the lungs of all five patients with ongoing infection, three of which had MABSC smooth colony morphology. Morphology data was not recorded for
Confocal laser scanning microscopy was accurate in determining the presence of NTM biofilm in the lungs of four patients. No mycobacteria were seen in the patient with resolved infection. Mycobacteria were observed in sparse intra-alveolar wall microcolonies surrounded by extracellular matrix (figure 1a and b). The NTM-specific PNA-FISH probe, while highly specific, had low yield, producing suboptimal visual bacterial morphology results, but the hybridisation signals were consistent and similar staining patterns were observed in pure MABSC biofilm culture (figure 1c). Staining specimens with auramine dye gave comparable morphology results (not shown), as did hybridisation with a uniBac probe (figure 1d). The uniBac probe was used to ensure that NTM-specific staining was not autofluorescence. Micrographs of the specific region shown in figure 1d was obtained from consecutive sections, stained with either the NTM probe (not shown) or the uniBac probe (figure 1d) and similar staining results were observed. Similar signals were not visible in H&E-stained specimens from the same area. Control hybridisation with a PNA-FISH probe specific for *Stenotrophomonas maltophilia* was performed in two patients with concomitant infection with this pathogen, confirming no cross-reactivity between probes. One patient was simultaneously culture positive for *Achromobacter xylosoxidans* and two patients for *P. aeruginosa*. Co-infection of two or more NTM species was not observed in any patient. The pattern of biofilm embedding deep in the alveolar wall was consistent in all four patients, but infrequently, single phagocytised mycobacteria and small biofilm aggregates in sputum were also observed (figure 1e).
While it has not previously been demonstrated that pulmonary MABSC is a biofilm infection, there is abundant indirect evidence to suggest this: NTM are known to be capable of biofilm growth in the environment and in laboratory culture [4], and biofilm-like aggregates are also occasionally visible in acid-fast smears from sputum-positive NTM patients (figure 1f). MAC, the most prevalent respiratory NTM, is a notorious biofilm producer in the domestic water supply [5]. *Mycobacterium ulcerans*, the cause of chronic ulcers in tropical environments, is another NTM species shown to cause biofilm infection [9]. Notably, biofilm infections are not exclusively surface phenomena, as aggregates can penetrate deep into tissue, as demonstrated in chronic wounds [10]. Our finding that MABSC might be capable of biofilm growth in the human lung has important clinical implications. Biofilm growth might play a role in explaining why susceptibility testing of MABSC is so poor at predicting therapeutic success. The mechanism involved could be that the diffusion of antibiotics into the biofilm core is inhibited due to an antibiotic concentration gradient across the aggregates, sparing viable bacteria [11]. It could also be due to the heterogeneity of metabolic states in biofilms, which protects dormant bacteria, allowing adaptive evolution of the persisting bacteria [12]. Notably, recognising that MABSC is a biofilm infection gives the potential for exploring biofilm-disrupting agents. In parallel with what is seen for other chronic pulmonary biofilm infections, early antibiotic treatment may prevent biofilm formation [11]. *P. aeruginosa* is known to grow as biofilms, both in the mucus of the conductive airways and in the respiratory zones in patients with cystic fibrosis, and may expel nonmucoid mutants, which proliferate as planktonic cells [13]. We found MABSC in biofilm aggregates, embedded in the interstitial spaces of the respiratory zones of the lung, surrounded by inflammation. This corresponds with our finding of MABSC microaggregates in expectorated sputum of MABSC patients from all stages of the disease (figure 1f). The *in vivo* localisation of the biofilm in the interstitial space supports the current notion that intravenous antibiotic treatment should play a prominent role in MABSC management, as high-dose systemic antibiotics are more likely than inhaled antibiotics to reach the respiratory zones. No patients from this series received MABSC inhaled antibiotic therapy at the time of transplantation and it should be noted that the conditions in the end-stage lungs of patients with cystic fibrosis in continuous anti-MABSC treatment might not be representative of all disease stages. The reason why very limited MABSC biofilm formation was seen in sputum in the conductive zones of the examined lungs may be that mycobacteria are dormant in sputum, which is predominantly anaerobic due to the activity of polymorphonuclear leukocytes, as previously demonstrated for the aerobic *S. maltophilia* [14].

Our finding that the *in vivo* MABSC biofilms appeared to be of the smooth colony morphology type concurs with reports that this morphology is associated with persistent infection [15]. While both smooth and rough MABSC colony morphologies share the characteristics of biofilm infection (organised colony architecture), the smooth morphotype is rich in glycopeptidolipid (GPL), which might be the main constituent of the extracellular matrix [15]. The rough morphotype, a virulence factor associated with cord formation, produces much less GPL in exchange for invasive growth [15].

In summary, we have shown that patients with cystic fibrosis and chronic pulmonary MABSC infection harbour mycobacterial biofilms, embedded in the alveolar walls of their end-stage lungs.

@ERSpublications
*Mycobacterium abscessus* complex can establish a biofilm infection in the lung, which has implications for treatment http://ow.ly/RSjGZ.

Tavs Qvist1,6, Steffen Eckhardt2,6, Kasper N. Kragh3, Claus B. Andersen1, Martin Iversen4, Niels Høiby2,5 and Thomas Bjarnsholt2

1Cystic Fibrosis Centre Copenhagen, Dept of Infectious Diseases, Rigshospitalet, Copenhagen University, Copenhagen, Denmark. 2Costerton Biofilm Centre, Dept of International Health, Immunology and Microbiology, Copenhagen University, Copenhagen, Denmark. 3Dept of Pathology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark. 4Dept of Cardiology, Lung Transplantation Unit, Rigshospitalet, Copenhagen University, Copenhagen, Denmark. 5Dept of Clinical Microbiology, Panum Institute, Building 24.1, Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark.

Correspondence: Thomas Bjarnsholt, Costerton Biofilm Centre, Dept of International Health, Immunology and Microbiology, Panum Institute, Building 24.1, Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark.

E-mail: tbjarnsholt@sund.ku.dk

Received: July 09 2015 | Accepted after revision: Aug 19 2015 | First published online: Oct 22 2015

Conflict of interest: None declared.

References

Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany

The emergence of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has re-established TB as a major worldwide health concern [1–3]. Compared with conventional TB drug regimens, treatments for MDR-TB and XDR-TB are more toxic, expensive and associated with poorer outcomes [3, 4]. In Germany, 102 (2.4%) of the 4318 TB cases reported for 2013 were MDR-TB, including 10 patients with XDR-TB [5], increasing from 54 (1.8%) cases in 2011 [5, 6]. An important factor behind the increase in Germany is migration, with more cases occurring in patients from the former Soviet Union than in native Germans [5].

Bedaquiline (BDQ) is a novel treatment that may be added for 24 weeks to a World Health Organization (WHO) recommended antibiotic background regimen (BR) for the treatment of MDR-TB [7]. WOLSON et al. [8] developed a comprehensive model looking at cost-effectiveness of BDQ plus BR (BDQ+BR) in the UK, over a substantially longer time horizon than a previously published WHO analysis [8, 9].

In this study, we report findings from an adapted version examining cost-effectiveness in the German healthcare system, where typically routine hospitalisation of patients with MDR-TB is carried out. A previous study of patients with MDR- TB in Germany found the total cost of treating to be €64 429.23 [10].

After adjustment to the perspective of the German Statutory Health Insurance (SHI) system, a cohort-based Markov model was used to estimate the cost-effectiveness of BDQ as an add-on for 24 weeks to a weighted antibiotic BR containing pyrazinamide, one injectable, one fluoroquinolone and one WHO group 4 agent, taking into account different strain resistance patterns as described in the C208 trial and following local guidelines [4, 7, 11]. This regimen of BDQ+BR was then compared with BR alone for the treatment of MDR- and XDR-TB. Comparison of BDQ with Delamanid, an alternative treatment option that was introduced later [12], was outside the focus of our analysis. Costs and effectiveness were discounted at an annual rate of 3% [13]. The time horizon for the model was 10 years. The model state structure was designed to reflect initial clinical care in patients with TB.